- Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and its subsidiary Intercept Pharma Europe Limited settled patent litigation with Dr. Reddy’s Laboratories Ltd (NYSE:RDY).
- The litigation concerns the submission by Dr. Reddy’s of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets before the expiration of the Company’s U.S. patents.
- Related: Intercept Shares Jump After Reissuing Annual Guidance.
- Under the terms of the agreement, Intercept granted Dr. Reddy’s a non-exclusive, non-sublicensable, non-transferable, royalty-free license to commercialize its generic version of Ocaliva in the U.S. commencing on October 26, 2035, or earlier under certain circumstances.
- Similar patent litigation previously disclosed by Intercept against five other generic filers seeking approval to market generic Ocaliva remains pending.
- Price Action: ICPT shares traded 0.94% lower at $17.90 on the last check Wednesday.
Related Posts
UBS Maintains Neutral on Atlantica Sustainable, Raises Price Target to $35
UBS analyst William Grippin maintains Atlantica Sustainable (NASDAQ:AY) with a Neutral and raises the price target from $33 to $35.
6 Hours Until Ethereum (ETH) Changes Forever: What You Need To Know Before The Merge
The Ethereum (CRYPTO: ETH) 'Merge' is scheduled to take place early Thursday morning (Sept. 15), somewhere between 1:00 AM and 2:00 AM EDT.
Analyst Ming-Chi Kuo Says “Apple’s 4Q23 iPhone Revenue And Profit Will Likely Be Better Than Expected And Easily Achieve YoY Growth Based On Early iPhone 15 Sales Results Survey” – Medium
https://medium.com/@mingchikuo/apples-4q23-iphone-revenue-and-profit-will-likely-be-better-than-expected-and-easily-achieve-yoy-ffdd4932d2c1 Apple's 4Q23 iPhone revenue and profit will likely be better than expected